Initiation of Sodium-Glucose Cotransporter 2 inhibitors after first hospitalization for heart failure: a population-based cohort study

Study type

• Study topic:
  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Drug utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Name of medicine:
  DAPAGLIFLOZIN
• Name of medicine, other:
  Empagliflozin
• Study drug International non-proprietary name (INN) or common name:
  DAPAGLIFLOZIN

  EMPAGLIFLOZIN
• Anatomical Therapeutic Chemical (ATC) code:
  (A10BK) Sodium-glucose co-transporter 2 (SGLT2) inhibitors

  Sodium-glucose co-transporter 2 (SGLT2) inhibitors
• Medical condition to be studied:
  Cardiac failure

Population studied

• Short description of the study population:
  Patients > 18 years discharged from first hospitalization for heart failure between 2021 and 2023
• Age groups:
  Adult and elderly population (≥18 years)
• Special population of interest:
  Renal impaired
• Special population of interest, other:
  Diabetes
• Estimated number of subjects:
  300000

Study design details

• Study design:
  Cohort study of patients discharged from first hospitalization for heart failure between 2021 and 2023.
• Main study objective:
  Proportion of SGLT-2i initiation at 30 days after discharge. ;
• Comparators:
  Not applicable.
• Outcomes:
  SGLT-2i initiation in the 30 days following hospital discharge.